The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
Torrent Pharmaceuticals has reported total income of Rs. 2,842 crores during the period ended December 31, 2024
700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
New Jersey-based manufacturing site to support innovative decentralized approach for improved patient experience
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Subscribe To Our Newsletter & Stay Updated
